ArticleNeurology. Genetics2026
Alternating Hemiplegia of Childhood: Development of a Disease-Specific Clinical Rating Scale.
Article in Neurology. Genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: Alternating hemiplegia of childhood (AHC) is a rare neurodevelopmental disorder, primarily caused by pathogenic variants in ATP1A3 that account for approximately 80% of cases. It is characterized by both paroxysmal and chronic neurologic features. Currently, no validated, disease-specific clinical outcome measures exist for AHC, limiting standardized assessment and longitudinal tracking. We aimed to develop and validate the AHC Rating Scale (AHC-RS), a tool applicable across all age groups. We hypothesized that the AHC-RS would demonstrate strong inter-rater reliability and construct validity. Methods: We conducted a multicenter observational study to assess the reliability and validity of the AHC-RS. Patients with clinically or genetically confirmed AHC-the sole inclusion criterion-were recruited from specialized neurology centers in Italy, Spain, and France. Each participant was visited following a standardized video protocol and evaluated independently by 4 trained neurologists using the AHC-RS. The primary outcome was inter-rater reliability, measured using the intraclass correlation coefficient (ICC). Construct validity was assessed through correlation with the Burke-Fahn-Marsden Dystonia Rating Scale. Results: Forty-eight patients, 45.8% men and 54.2% women (median age: 18.6 years - SD: 12.4, range 2-48), were included. The AHC-RS evaluates 4 different domains: Paroxysmal Nonepileptic Manifestations, Epilepsy, Nonparoxysmal Manifestations, and Adaptive Capacities. Inter-rater reliability was excellent across all domains (ICC: 0.95-0.99). Construct validity was supported by a moderate correlation between the AHC-RS total score and the Burke-Fahn-Marsden Scale (Spearman rho = 0.58; 95% CI 0.29-0.78). A strong correlation was observed between the Nonparoxysmal Score and the Adaptive Score ( Discussion: The AHC-RS shows excellent inter-rater reliability and good construct validity, supporting its use as a disease-specific outcome measure for AHC. These findings confirm clinical observations that paroxysmal and chronic symptoms may progress independently and highlight the greater impact of nonparoxysmal features on long-term functional outcomes. This scale offers a standardized tool for both clinical evaluation and future therapeutic trials. Further validation in larger and more diverse cohorts is warranted.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.